Galderma unveils new data from investigator-initiated trial addressing menopausal skin

Pharmaceutical company Galderma has announced new data from an investigator-initiated trial (IIT) addressing the treatment of aesthetic changes during menopause.

The ongoing trial highlights the role of Restylane Skinboosters™ and Sculptra on skin skin barrier function, hydration and patient satisfaction.

New interim results from the nine-month investigator-initiated study led by Dr. Andreas Nikolis highlight promising advancements in the treatment of menopausal skin using a dual-sequence approach.

The study evaluated the combined use of Restylane Skinboosters and Sculptra on the face and décolletage of menopausal women. Findings showed progressive and meaningful improvements in skin quality, with the greatest gains in hydration observed when treatment began with Skinboosters.

Hydration remains a key concern for menopausal patients, and results demonstrated measurable enhancements in skin-barrier function, texture and overall quality in both treatment sequences. Skinboosters delivered early indicate improvements in hydration and surface irregularities, while Sculptra supported longer-term collagen stimulation, restoring firmness, volume and radiance over time.

Patient-reported outcomes mirrored clinical findings, with satisfaction scores rising steadily throughout the study and reaching high levels by Month 6.

According to Dr. Nikolis, the research addresses an important gap in aesthetic medicine, noting that menopausal skin changes, such as dryness and reduced collagen, have historically been underrepresented in clinical studies.

The findings suggest that a sequenced combination approach may offer an effective, evidence-based strategy for improving skin health and patient satisfaction in this growing demographic.

Dr Andreas Nikolis, study lead investigator and board-certified plastic surgeon said: “Menopause is associated with a distinct and often under-recognized set of skin changes, including dryness, barrier dysfunction, and progressive declines in skin quality. This first-of-its-kind clinical study is helping address an important unmet need by generating objective data in a population that has historically been overlooked in aesthetic research.

“The interim findings are highly encouraging, demonstrating meaningful improvements in skin hydration and collagen-related skin quality over time. Equally important, these measurable clinical benefits are mirrored by rising patient satisfaction throughout the study.

“For clinicians, these early results offer valuable evidence-based insight into how we can better support aging menopausal patients with treatment strategies that are tailored to the biologic changes of this stage of life.”